Major Outcomes With Personalized Dialysate TEMPerature (MyTEMP)
Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
About this trial
This is an interventional prevention trial for Kidney Diseases focused on measuring Cluster randomized Controlled Trial, Personalized Dialysate Temperature, Cooler Dialysate Temperature, Mortality, Cardiovascular Events, Myocardial Infarction, Ischemic Stroke, Congestive Heart Failure, Dialysis Solutions
Eligibility Criteria
This pragmatic cluster randomized controlled trial has only two inclusion criteria:
Inclusion Criteria:
- The hemodialysis centre must have cared for a minimum of 15 outpatients being treated with maintenance in-centre hemodialysis on January 1st, 2017.
- The medical director of the hemodialysis centre (who acted as the centre's gatekeeper) must have been willing for their centre to adopt the randomly allocated dialysate temperature protocol for the duration of the trial.
Exclusion Criteria:
- The centre cares for less than 15 patients being treated with conventional in-centre hemodialysis.
Sites / Locations
- London Health Sciences Centre
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Personalized Dialysate Temperature
Fixed Dialysate Temperature at 36.5°C
Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C